EP Vantage submits: Johnson and Johnson 's ( JNJ ) new licensing agreement with Gilead Sciences ( GILD ) for its protease inhibitor Prezista to develop a new combination drug using booster drug cobicistat says a lot about the clever life-cycle management strategy J&J has come up with for the drug. ... By Vatalyst : Johnson & Johnson ( JNJ ) is one of the world's leading drug manufacturers and researchers while providing medical supplies both for home use and to hospitals around the world. Its extensive portfolio of home brands includes names such as Tylenol, Sudafed, Neosporin, Band-Aid, ... Johnson & Johnson ( JNJ ) will realize an after-tax gain of $213M from the sale of 82M ADSs in Elan back to the Irish company. J&J had tendered 107.4M shares in Elan's repurchase program . ( PR ) Post your comment! Johnson & Johnson ( JNJ ) has won the second lawsuit over its ASR hip implant, with a jury in Chicago ruling that the company didn't inappropriately market the all-metal device, which the plaintiff argued J&J knew was flawed. The verdict follows a decision in LA to award $8.3M against the company. ... A jury is due to start hearing arguments today about the punitive damages that Johnson & Johnson ( JNJ ) should pay for damage caused to a South Dakota patient by the company's Gynecare Prolift vaginal mesh. The jury yesterday ordered J&J to pay Linda Gross $3.35M. J&J faces 4,000 lawsuits over the ... Johnson & Johnson ( JNJ ) agrees to pay a total of $600K to resolve three lawsuits over problems caused by its defective ASR hip implants, Bloomberg reports. The cases are the first out of around 8,000 lawsuits to be settled, with J&J facing a bill of up to $2B. The company has already spent $800M ... Jury selection is due to begin today in the first trial over Johnson & Johnson's ( JNJ ) Gynecare Prolift vaginal mesh implant, which a South Dakota woman says has caused her constant pain and has led to 18 operations. The complaint is one of 1,800 against Prolift, which J&J has said it will stop ... By Bio Vantage : The FDA will decide on the fate of Invokana (canagliflozin) this Friday (March 29, 2013). This is an investigational drug submitted by Johnson and Johnson ( JNJ ) last May for the treatment of adult patients with type 2 diabetes. If approved, this will be the first-in-class SGLT2 ... To overcome a recent legal ruling in favor of Biogen Idec BIIB, Elan ELN and Johnson & Johnson JNJ modified the terms of their merger. Specifically, the two companies eliminated J&J's strategic option to help Elan finance the acquisition of full rights to Tysabri from Biogen, should Biogen undergo ... Johnson & Johnson JNJ reported fourth quarter results that matched our expectations and we are holding firm to our fair value estimate. Excluding the impact of foreign exchange rates, total sales increased 5% year-over-year, with all of the company's divisions contributing gains. As a trend we ...